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and presence of diabetes or hypertension are all as-
sociated with increased 30-day mortality after CABG. 
CONCLUSION: The incidence of major adverse events
in CABG patients varies widely across different studies
and patient populations. This heterogeneity must be con-
trolled when using the literature to benchmark safety.
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Current data are limited regarding the effects of statins in
the naturalistic setting of clinical practice.
OBJECTIVES: This study sought to determine the effects
of statins on the lipid proﬁle and target LDL-cholesterol
(LDL-C) attainment in this setting. 
METHODS: Patients newly initiated on atorvastatin, 
ﬂuvastatin, pravastatin, or simvastatin from 1/99 to 6/99
were retrospectively identiﬁed from a southeastern U.S.
health plan database. A parallel design incorporated four
study arms based on the statin prescribed. Exclusion 
criteria included statin therapy in the prior 6 months, less
than 90 days of statin therapy, switching of statin, use of
combination dyslipidemia therapy, or non-continuous
enrollment in the health plan. Changes in lipid subfrac-
tions and attainment of LDL-C goal based on NCEP ATP
II guidelines were evaluated with OLS and logistic regres-
sion techniques utilizing clinically relevant covariates.
RESULTS: A total of 2,429 patients (age = 62 ± 13 years,
47.8% male) were identiﬁed. Comorbidities included
73% hypertension, 24% diabetes, and 34% atheroscle-
rotic vascular disease. Median duration of statin therapy
was 19.4 months. Patients receiving atorvastatin had sig-
niﬁcantly greater mean absolute (and percentage) reduc-
tions in LDL-C and triglycerides compared to the other
statins in both the unadjusted and adjusted results (all 
p < 0.05 vs. atorvastatin). Differences in HDL-cholesterol
(HDL-C) were small, however, a statistically signiﬁcant
increase was observed with simvastatin compared to 
atorvastatin (p < 0.05). Also, a signiﬁcantly greater per-
centage (unadjusted, adjusted) of patients reached their
NCEP LDL-C goal on atorvastatin (74.0%, 73.0%) com-
pared with ﬂuvastatin (52.0%, 51.0%), pravastatin
(58.3%, 56.4%) and simvastatin (69.0%, 69.4%), and
atorvastatin patients reached goal faster than the other
statins (median: 184 days vs. 215–357 days, all p < 0.05
vs. atorvastatin). 
CONCLUSION: Patients prescribed atorvastatin had 
statistically signiﬁcant improvements in LDL-C and
triglycerides, though not in HDL-C, compared to those
prescribed other statins. In addition, atorvastatin patients
attained LDL-C goal more often and in a shorter 
timeframe.
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OBJECTIVES: The beneﬁts of aggressive lipid-lowering
(L-L) therapy among patients with an elevated risk of
coronary heart disease (CHD) are well established, but
longitudinal data from clinical practice are limited. Our
objective was to assess trends in the rate of cholesterol
goal attainment (based on NCEP criteria) among moder-
ate- and high-risk patients in a managed care setting. 
METHODS: A retrospective cohort design was employed
using linked pharmacy claims, medical claims, and clini-
cal laboratory data from members of a Northeastern US
group model HMO. The study cohort included patients
55+ years of age who were newly treated with L-L drug
therapy between 1995 and 1998, had an LDL-C value
over 160mg/dL within 90 days prior to treatment, and
had no history of CHD but at least one CHD risk factor
other than age. The duration of follow-up was 1 year.
RESULTS: A total of 1044 patients were identiﬁed. The
average age was 68 years and 41% were male. The mean
baseline LDL-C level was 197mg/dL. Most patients
(86%) began treatment with a statin, and adherence
(evaluated by “covered days”) averaged 61%. The mean
decline in LDL-C was 25%. Target LDL-C levels were
reached by 34% of this population. The rate of LDL-C
goal attainment increased from 18% in the 1995 cohort
to 46% in the 1998 cohort. The likelihood of reaching
goal was positively associated with cohort year (P < 0.01),
male gender (P = 0.05), and beginning treatment with a
statin (P = 0.04) and negatively associated with initial
LDL-C level (P < 0.01). Age and the number of risk
factors were not associated with goal attainment.
CONCLUSIONS: In this primary prevention population,
cholesterol management improved substantially over
time. Nonetheless, most patients still did not achieve their
target LDL-C levels, indicating that further research is
required to identify steps for increasing the effectiveness
of cholesterol treatment.
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OBJECTIVES: Warfarin anticoagulation has been shown
to effectively decrease the rate of thromboembolism (TE),
with an associated increased rate of bleeding. Maximiz-
ing the beneﬁt and minimizing the risk depends on 
maintaining patients in a narrow therapeutic range for
prothrombin time (measured as INR); increased percent-
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age of time spent in target range (TTR) is predictive of
better clinical outcomes. However, strategies to improve
TTR can be costly. To allow local clinical policy makers
to determine whether these strategies can be justiﬁed, we
developed a general approach to estimating bleeding and
TE rates associated with a given population distribution
of INR. 
METHODS: We used data from a large cohort 
(Cannegieter, 1995) to derive a logistic equation for base-
line absolute risk of bleeding as a function of INR. Based
upon a separate large cohort of patients (Fihn, 1993) with
various time since initiation of therapy we derived a risk
ratio that modiﬁes the above baseline relationship in
order to take into account time since initiation of therapy.
A similar strategy was used to estimate TE, using INR
and indication (mechanical valve versus atrial ﬁbrillation)
as predictors.
RESULTS: The model for bleeding was: logit (p) = -8.84
+.83 INR +.64 EARLY, where EARLY = 1 if the patient
is in the ﬁrst 3 months of anticoagulation, and 0 other-
wise. The ﬁnal model for TE was: logit (p) = -73 - 1.17
INR - .64(AF), where AF = 1 if the indication is atrial
ﬁbrillation and 0 if the indication is mechanical heart
valve. The integral of these logistic equations, weighted
by a given population distribution of INR, provides 
population estimates of annual bleed and TE rates. 
CONCLUSION: Existing epidemiological data can
provide tailored estimates of concrete beneﬁts resulting
from improving the quality of anticoagulation.
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Coronary heart disease (CHD) is the leading cause of
adult deaths in America. Multiple trials have shown that
by modifying cholesterol levels, risk of CHD can be
decreased.
OBJECTIVES: Objectives of this research were to assess
the impact of a pharmacist-managed ambulatory lipid
clinic (PMALC) on CHD-risk proﬁle, effectiveness and
cost of care in patients with hyperlipidemia in a VA
ambulatory clinic. 
METHODS: This longitudinal research began with a 
retrospective review of 30 randomly selected charts using
indicators consistent with NCEP-ATPII guidelines. This
review led to opening the PMALC. After 9 months, 80
randomly selected charts were reviewed (40 PMALC + 40
non-PMALC). To further evaluate the impact of the
PMALC on patient outcomes, researchers took part in a
prospective, randomized, controlled, multi-centered trial.
RESULTS: Initial review suggested that 60% of patients
did not have baseline and follow-up lipid panels, 93% did
not have baseline liver function tests (LFT’s), 55% had
no documented change in LDL after 3 months, 16%
reached LDL goal of <130mg/dL, and 6% reached LDL
goal of <100mg/dL. The second review revealed 100%
of PMALC patients versus 40% of non-PMALC patients
with baseline lipid proﬁles, baseline LFT’s were measured
in 100% of PMALC patients versus 35% of non-PMALC
patients, 66% of PMALC patients reaching an LDL goal
of <130mg/dL versus 36% of non–PMALC patients,
70% of PMALC patients reaching an LDL goal of 
<100mg/dL versus 14% of non—PMALC patients. Non-
PMALC patients utilized more medication, costing
$62/month versus PMALC patients $38/month.
CONCLUSIONS: Pharmacist-managed ambulatory lipid
clinic programs ensured more patients were treated to
NCEP ATP-II guideline goals, offered a cost-effective
option for treating patients, and decreased patients’
overall CHD risk proﬁle versus standard care from
primary care teams.
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Recent studies have shown that reductions in cholesterol
levels among patients with coronary heart disease (CHD)
reduce mortality.
OBJECTIVE: To determine screening rates for hyperlipi-
demia among health plan members recently hospitalized
for CHD. 
METHODS: Utilizing data from a large managed care
company in a major metropolitan area, member data
were selected from the health plan pharmacy, medical and
labs claims databases from April 1, 1998 to April 1, 2000.
Selection criteria included an age of 35 years and older,
continuous enrollment in the plan for the previous 24
months, having one or more inpatient claim during
November 1, 1998 to November 1, 1999 indicating
CHD, and not having a pharmacy claim for a cholesterol
lowering medication within 6 months prior to 
hospitalization.
RESULTS: Of the 74,097 plan members enrolled during
the study period, 340 members met inclusion criteria. Of
these only 7 (2.1%) had prescription claims for a lipid
lowering medications within six months prior to the
admission date and were eliminated from the analysis.
The mean age of the remaining 333 members was 57.6
years (range 35–79). A majority (61.6%, n = 205) of
members were male. A total of 436 lab tests for any 
cholesterol lab value, including total cholesterol, LDL
cholesterol, HDL cholesterol and triglycerides, were com-
pleted for only 66 (19.8%) of 333 members. The mean
number of lab tests for these members was 6.6 (Range 4
to 24).
CONCLUSIONS: The major ﬁnding of this analysis was
the low percentage of members who received any choles-
terol lab test following a hospital admission for CHD.
This suggests that the majority of these high-risk patients
